Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: Phase II Trial of Sorafenib in Patients With Extensive Keloids
Brief Summary:
Treatment of keloid disorder is an area of unmet medical need. Current treatments for keloid partially address small and localized keloids, yet there are no wholly satisfactory or effective treatments for patients with extensive keloids. Such patients may benefit from effective systemic treatments.
Sorafenib has the potential to regulate the three known dysregulated biological pathways in keloid tissue.